Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue: −31.8%
EPS: −123.8%
Free cash flow: −268.5%
Total debt: +153.3%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%

Follow LGND

Alert me

Market cap: $6.0B
P/E: 118×
Fwd P/E: 88.3×
Dividend yield: —
F-score: 6/9
Altman Z: 5.45
Beneish M: −4.02
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Ligand Pharmaceuticals Incorporated (LGND) revenue by segment, product and region

	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019
Captisol	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Royalty, Promacta	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Captisol - COVID	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Kyprolis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Captisol	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Milestone	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Evomela	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
License Fees, Milestones, and Other Product, Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Teriparatide injection	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Contract revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Rylaze	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Contract revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Royalties	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Ligand Pharmaceuticals Incorporated (LGND) revenue by segment, product and region

Stockrow Weekly